CJC-1295 vs Tesamorelin
Both are GHRH analogs that prompt the pituitary to release its own growth hormone. Only one is FDA-approved, and only for a narrow, specific indication.
Short answer
The clearest difference is regulatory. Tesamorelin is FDA-approved, and CJC-1295 is not FDA-approved. Tesamorelin fits a reader who wants an FDA-approved product, though that approval does not cover every use it is marketed for, while CJC-1295 is marketed for muscle and recovery. On the evidence, CJC-1295 has human clinical data and tesamorelin has approval-level evidence.
CJC-1295
Sustained GH/IGF-1 rise shown in humans — a surrogate marker, not the body-composition outcome it is sold for.
Full CJC-1295 evidence reviewTesamorelin
Egrifta
FDA-approved specifically for HIV-associated visceral fat — not a general weight-loss drug.
Full Tesamorelin evidence reviewCJC-1295 vs Tesamorelin: head to head
- FDA status / approved use
CJC-1295
Not approved for any marketed use; sold as a research-use-only productTesamorelin
FDA-approved as Egrifta only to reduce abdominal fat in HIV-associated lipodystrophy- Marketed for
CJC-1295
Muscle, recovery, 'anti-aging'Tesamorelin
Visceral fat (often sold for 'fat loss')- Outcome areas
CJC-1295
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespanTesamorelin
Weight loss / appetite- Evidence grade
CJC-1295
Clinical dataTesamorelin
FDA-approved- How it works
CJC-1295
Long-acting GHRH analog that stimulates growth hormone releaseTesamorelin
GHRH analog that prompts the pituitary to release the body's own growth hormone- Route and dosing
CJC-1295
InjectionTesamorelin
Injection, 2 mg daily in pivotal trials- Headline human result
CJC-1295
Single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trialsTesamorelin
Visceral fat fell 15.2% vs a 5.0% gain on placebo at 26 weeks in a 412-patient Phase 3 trial- Strongest evidence
CJC-1295
Teichman, JCEM 2006CJC-1295 evidence reviewPubMed 16352683Tesamorelin
Falutz, NEJM 2007Tesamorelin evidence reviewPubMed 18057338- Key safety signal
CJC-1295
No long-term human safety data; chronic GH/IGF-1 stimulation raises concernsTesamorelin
Can raise blood glucose and worsen glucose tolerance; raises IGF-1, so approved use involves monitoring- How it is obtained
CJC-1295
Sold gray-market as a research chemical; no approved or legitimately compounded human productTesamorelin
Prescription drug
| CJC-1295 | Tesamorelin | |
|---|---|---|
| FDA status / approved use | Not approved for any marketed use; sold as a research-use-only product | FDA-approved as Egrifta only to reduce abdominal fat in HIV-associated lipodystrophy |
| Marketed for | Muscle, recovery, 'anti-aging' | Visceral fat (often sold for 'fat loss') |
| Outcome areas | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan | Weight loss / appetite |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Long-acting GHRH analog that stimulates growth hormone release | GHRH analog that prompts the pituitary to release the body's own growth hormone |
| Route and dosing | Injection | Injection, 2 mg daily in pivotal trials |
| Headline human result | Single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trials | Visceral fat fell 15.2% vs a 5.0% gain on placebo at 26 weeks in a 412-patient Phase 3 trial |
| Strongest evidence | Teichman, JCEM 2006CJC-1295 evidence reviewPubMed 16352683 | Falutz, NEJM 2007Tesamorelin evidence reviewPubMed 18057338 |
| Key safety signal | No long-term human safety data; chronic GH/IGF-1 stimulation raises concerns | Can raise blood glucose and worsen glucose tolerance; raises IGF-1, so approved use involves monitoring |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
This is the sharpest evidence gap in the GH-axis category. Tesamorelin is an approved drug, sold as Egrifta, indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; randomized, placebo-controlled phase 3 trials showed it significantly reduced visceral adipose tissue versus placebo, with the effect reversing after stopping. CJC-1295 is not approved for anything and is sold as research-only material; its best human evidence is a controlled study showing single injections produced sustained, multi-day elevations in GH and IGF-1, which is a surrogate marker rather than the body-composition result it is marketed for. The two have not been compared head to head, and tesamorelin's approval does not carry over to anti-aging, general fat loss, or healthspan in healthy adults; that use is an extrapolation to a different population and a different goal.
CJC-1295 fits if
CJC-1295 is worth reading about if you want to see what a genuine, measured pharmacodynamic effect looks like, and why a multi-day rise in GH and IGF-1 still is not an outcome.
Tesamorelin fits if
Tesamorelin is the relevant molecule if the question is HIV-associated lipodystrophy specifically, where a clinician-supervised, approved product with phase 3 data and monitoring actually exists.
CJC-1295 vs Tesamorelin: common questions
- Is tesamorelin FDA-approved but CJC-1295 not?
- Yes. Tesamorelin is FDA-approved as Egrifta only to reduce abdominal fat in HIV-associated lipodystrophy. CJC-1295 is not approved for any marketed use; sold as a research-use-only product.
- Which has stronger human evidence, CJC-1295 or tesamorelin?
- Tesamorelin. It has approval-level evidence (key source: Falutz, NEJM 2007), while CJC-1295 has human clinical data (key source: Teichman, JCEM 2006).
- What are the main safety concerns with CJC-1295 and tesamorelin?
- CJC-1295 has no long-term human safety data; chronic GH/IGF-1 stimulation raises concerns. Tesamorelin can raise blood glucose and worsen glucose tolerance; raises IGF-1, so approved use involves monitoring.
Key studies behind each
CJC-1295
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. PubMed 19289567
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PubMed 25331030
Tesamorelin
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PubMed 18057338
- Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. PubMed 20554713
- Sattler FR. (2013). Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. PubMed 24054930
The full evidence reviews
- Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides
They reliably raise growth hormone, and that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.
Updated October 2026
- Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence
A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm CJC-1295 & Ipamorelin availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: California Trim ClinicDr. Gillis' Wellness CenterElitePhysiqMDEmbraceRXIron Med RXJune Health